Aldeyra Therapeutics Inc
ALDX5.385USD
-0.155-2.80%
Market hours （ET）Quotes delayed by 15 min
323.98MMarket Cap
LossP/E TTM
More Details of Aldeyra Therapeutics Inc Company
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Aldeyra Therapeutics Inc Info
Ticker SymbolALDX
Company nameAldeyra Therapeutics Inc
IPO dateMay 02, 2014
CEOBrady (Todd C)
Number of employees9
Security typeOrdinary Share
Fiscal year-endMay 02
Address131 Hartwell Avenue
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone17817614904
Websitehttps://www.aldeyra.com/
Ticker SymbolALDX
IPO dateMay 02, 2014
CEOBrady (Todd C)
Company Executives of Aldeyra Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Independent Director
--
--
Ms. Nancy B. Miller-Rich
Ms. Nancy B. Miller-Rich
Independent Director
Independent Director
--
--
Mr. William (Chip) Clark
Mr. William (Chip) Clark
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Alfieri
Mr. Michael (Mike) Alfieri
Principal Financial Officer and Principal Accounting Officer
Principal Financial Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
9.10%
Perceptive Advisors LLC
8.68%
The Vanguard Group, Inc.
5.97%
BlackRock Institutional Trust Company, N.A.
5.81%
Ardsley Advisory Partners LP
3.16%
Other
67.28%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
9.10%
Perceptive Advisors LLC
8.68%
The Vanguard Group, Inc.
5.97%
BlackRock Institutional Trust Company, N.A.
5.81%
Ardsley Advisory Partners LP
3.16%
Other
67.28%
Shareholder Types
Shareholders
Proportion
Hedge Fund
20.62%
Investment Advisor
19.08%
Investment Advisor/Hedge Fund
13.86%
Private Equity
8.68%
Research Firm
3.30%
Individual Investor
3.09%
Pension Fund
0.29%
Family Office
0.27%
Bank and Trust
0.10%
Other
30.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
257
39.75M
62.22%
-36.54K
2025Q3
293
39.78M
67.43%
+4.94M
2025Q2
293
34.50M
64.74%
+807.50K
2025Q1
306
38.11M
75.15%
-6.76M
2024Q4
299
38.34M
74.88%
+752.39K
2024Q3
287
37.69M
73.36%
+1.21M
2024Q2
282
36.36M
75.77%
-918.00K
2024Q1
286
36.60M
74.25%
-7.13M
2023Q4
287
36.20M
72.36%
-697.70K
2023Q3
289
38.63M
87.46%
-1.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
5.48M
9.14%
--
--
Jun 30, 2025
Perceptive Advisors LLC
4.05M
6.76%
-824.22K
-16.90%
Jun 30, 2025
The Vanguard Group, Inc.
3.50M
5.85%
-216.43K
-5.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.54M
5.91%
+127.13K
+3.73%
Jun 30, 2025
Ardsley Advisory Partners LP
2.05M
3.42%
+300.00K
+17.14%
Jun 30, 2025
AQR Capital Management, LLC
1.47M
2.46%
+1.08M
+275.44%
Jun 30, 2025
Brady (Todd C)
1.42M
2.38%
+267.69K
+23.16%
Apr 14, 2025
D. E. Shaw & Co., L.P.
487.67K
0.81%
+336.03K
+221.59%
Jun 30, 2025
Kingdon Capital Management, L.L.C.
1.33M
2.22%
+552.79K
+70.96%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.15M
1.91%
+8.77K
+0.77%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.47%
Vanguard US Momentum Factor ETF
0.05%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
Vanguard US Momentum Factor ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aldeyra Therapeutics Inc?
The top five shareholders of Aldeyra Therapeutics Inc are:
Knoll Capital Management, LLC holds 5.48M shares, accounting for 9.14% of the total shares.
Perceptive Advisors LLC holds 4.05M shares, accounting for 6.76% of the total shares.
The Vanguard Group, Inc. holds 3.50M shares, accounting for 5.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.54M shares, accounting for 5.91% of the total shares.
Ardsley Advisory Partners LP holds 2.05M shares, accounting for 3.42% of the total shares.
Knoll Capital Management, LLC holds 5.48M shares, accounting for 9.14% of the total shares.
Perceptive Advisors LLC holds 4.05M shares, accounting for 6.76% of the total shares.
The Vanguard Group, Inc. holds 3.50M shares, accounting for 5.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.54M shares, accounting for 5.91% of the total shares.
Ardsley Advisory Partners LP holds 2.05M shares, accounting for 3.42% of the total shares.
What are the top three shareholder types of Aldeyra Therapeutics Inc?
The top three shareholder types of Aldeyra Therapeutics Inc are:
Knoll Capital Management, LLC
Perceptive Advisors LLC
The Vanguard Group, Inc.
Knoll Capital Management, LLC
Perceptive Advisors LLC
The Vanguard Group, Inc.
How many institutions hold shares of Aldeyra Therapeutics Inc (ALDX)?
As of 2025Q4, 257 institutions hold shares of Aldeyra Therapeutics Inc, with a combined market value of approximately 39.75M, accounting for 62.22% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -5.21%.
What is the biggest source of revenue for Aldeyra Therapeutics Inc?
In --, the -- business generated the highest revenue for Aldeyra Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
